Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals

Obeticholic acid (OCA) is a farnesoid X receptor agonist used in primary biliary cholangitis (PBC) treatment. Recent studies have expanded OCA use for NASH treatment and results from phase 3 clinical trial have shown beneficial reduction of ≥1 stage of fibrosis with no NASH worsening. However, safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Cheng Han, Tang, Ansel Shao Pin, Xiao, Jieling, Wong, Zhen Yu, Yong, Jie Ning, Fu, Clarissa E., Zeng, Rebecca W., Tan, Caitlyn, Wong, Gabriel Hong Zhe, Teng, Margaret, Chee, Douglas, Tan, Darren Jun Hao, Chan, Kai En, Huang, Daniel Q., Chew, Nicholas W.S., Nah, Benjamin, Siddqui, Mohammad S., Sanyal, Arun J., Noureddin, Mazen, Muthiah, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915961/
https://www.ncbi.nlm.nih.gov/pubmed/36757421
http://dx.doi.org/10.1097/HC9.0000000000000005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915961/
https://www.ncbi.nlm.nih.gov/pubmed/36757421
http://dx.doi.org/10.1097/HC9.0000000000000005

Ejemplares similares